Kenneth Blum* , David Baron1 , Thomas McLaughlin , Panayotis K. Thanos , Catherine Dennen , Mauro Ceccanti , Eric R. Braverman , Alireza Sharafshah , Kai-Uwe Lewandrowski , John Giordano and Rajendra D. Badgaiyan
Annotated bibliography of genetic addiction risk severity (GARS) publications, pro-dopamine regulation in nutraceuticals (KB220 nutraceutical variants), and policy documents. Further research is required to encourage the field to consider “Reward Deficiency Syndrome (RDS) Anti-addiction Modeling” which involves early risk identification by means of genetic assessment similar to GARS, followed by induction of dopamine homeostasis by means of genetically guided pro-dopamine regulation similar to KB220. These results suggest that genetically based treatments may be a missing piece in the treatment of substance use disorder (SUD).
Published on: April 05, 2024
Citation: Blum K, Baron D, McLaughlin T, Thanos PK, Dennen C, Ceccanti M, Braverman ER, Sharafshah A, Lewandrowski KU, Giordano J, Badgaiyan RD. 2024. Summary Document Research on RDS Anti-addiction Modeling: Annotated Bibliography. J Addict Psychiatry 8(1): 1-33
Downloads